Catalyst Pharmaceuticals Gets FDA OK for Firdapse in Children

 Catalyst Pharmaceuticals Inc. on Thursday said the U.S. Food and Drug Administration approved the expanded use of its Firdapse treatment for Lambert-Eaton myasthenic syndrome to include children.

The Coral Gables, Fla., biopharmaceutical company said the drug is now available for patients ages 6 through 17 with the rare condition, in which the immune system attacks the neuromuscular junctions.

In 2018, the FDA approved Firdapse for adults with Lambert-Eaton myasthenic syndrome.

https://www.marketscreener.com/quote/stock/CATALYST-PHARMACEUTICALS-36303/news/Catalyst-Pharmaceuticals-Gets-FDA-OK-for-Firdapse-in-Children-41891291/